Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Barbara Holzer, Broadcast Manager
w. (202) 588-7716
bholzer@citizen.org

Karilyn Gower, Press Officer
w. (202) 588-7779
kgower@citizen.org

Symone Sanders, Communications Officer, Global Trade Watch division
w. (202) 454-5108
ssanders@citizen.org

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog
Facebook/publiccitizen

Follow us on Twitter

 

July 15, 2010

Weight Loss Drug Too Dangerous to Be Allowed On Market

Public Citizen's Dr. Sidney Wolfe Testifies Before FDA Advisory Committee


Dr. Sidney Wolfe, director of Public Citizen's Health Research Group, testified today before an FDA advisory committee about a proposed new weight-loss drug, Qnexa. In his testimony, prepared by himself and Dr. Charles Preston of the Johns Hopkins Bloomberg School of Public Health, he said the drug is too dangerous too approve. Qnexa is a combination of two old drugs, phentermine and topiramate, each of which has significant risks. One is an amphetamine; the other, an anti-seizure medication.

Phentermine affects many different organ systems, including the neurologic, cardiovascular, and gastrointestinal. It increases heart rate and blood pressure, heightens wakefulness, and decreases appetite.

Studies of topiramate show that cognition is impaired in people who take the drug, particularly regarding attention, memory, and language. The same is seen with Qnexa. It was hypothesized that by adding an amphetamine, the negative cognitive effects of topiramate might be mitigated. But we see just the opposite-that the combination is worse than the topiramate alone. Further, anti-epileptic drugs - especially topiramate - have long been known to increase the risk of suicidal ideation relative to placebo.

Qnexa carries a long list of serious side effects. In fact, adverse events were the major reason patients failed to complete the trials of the drug; 18% of high-dose subjects withdrew due to an adverse event, compared to 9% for a placebo.

Perhaps one of the most important prior studies relevant to today’s decision was a randomized, placebo controlled trial of topiramate controlled release (CR) for overweight and obese patients with type 2 diabetes. The treatment group underwent 16 weeks of therapy, up to a dose of 175 mg/day. The investigators found that the cognitive and psychiatric effects were similar to those seen with Qnexa-- namely higher rates of anxiety, memory difficulties, and insomnia compared to placebo-- and they concluded that the “CNS and psychiatric adverse event profile of topiramate CR makes it unsuitable for the treatment of obesity and diabetes.”  "We couldn’t agree more strongly," Dr. Wolfe said.

To read the testimony, visit http://www.citizen.org/hrg1914.

###

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.